Clinical trials

The following list shows the clinical trials currently open at the two sarcoma centres in London and the South East: University College London (UCLH) and The Royal Marsden (RMH). For further information please contact the research nurses at each site:

Last updated January 2025

Name Description Type Centre Age
ADCT-601 A Phase Ib, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Selected Advanced Solid Tumors Phase Ib RMH
AGENUS C-800-01 A Phase I Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034 (balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer Phase I RMH
BRIGHTLINE 4 A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pretreated advanced dedifferentiated liposarcoma Phase III RMH
EHE Biobank UK Biobank for epithelioid haemangioendothelioma RMH
EHE Study Milan Evaluation of cytokines and hormonal profile as biomarker in epithelioid haemangioendothelioma RMH
FaR RMS An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma RMH,
UCLH		 >12 months, ≤40 years
GIST Biobank Biobank for GIST RMH
ICONIC Improving outcomes through collaboration in osteosarcoma UCLH
IDRx First in Human study of IDRx-42 in patients with metastatic/unresectable GIST following progression on imatinib only or treatment naïve Phase lb RMH
INSIGHT Ripretinib vs Sunitinib. GIST with KIT Exon 11 and Co occurring KIT Exons 17 and/or 18 Mutations Phase III RMH
Inter-Ewings International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (INTER-EWING-1) UCLH >2 years
INBRX-109 (ChonDRAgon) A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma Phase II RMH,
UCLH		 >18 and <85 years
KINDRED The International Sarcoma Kindred Study: a global multi‐site prospective cancer genetics study. Translational RMH
UCLH		 ≥15 years
NEWBAY A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Malignancies Phase I RMH
OligoRARE (EORTC 1945) Stereotactic body radiotherapy in addition to standard of care treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial Phase III RMH
Pharma Mar Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma Phase IIb/III RMH,
UCLH		 >18
PREDICT B Predicting radiotherapy response, toxicities and quality of life related functional outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study RMH,
UCLH		 ≥16 years
Radiomics in Liposarcoma Radiomics In Liposarcoma RMH
rEECur International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma. Phase II/III RMH
UCLH		 >4 years and < 50 years
RT Immune A European, Multicentre, Randomized, Open-label, Phase II Trial, aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localised soft tissue sarcomas patients to be treated with radiotherapy. Phase II RMH
STRASS 2 A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone. Phase III RMH